PD-1/PD-L1 targeting has been well-studied in EOC, despite the fact that only 33% of high grade ovarian cancer patients are considered PD-L1 positive and no significant correlation exists between PD-L1 levels and survival (41). This evidence concerns the gene CD274 and ovarian cancer.